Last updated: May 18, 2026
What sermorelin is
Sermorelin acetate (also called GHRH 1-29) is a synthetic analog of the first 29 amino acids of human growth hormone-releasing hormone. Despite being a fragment, the (1-29) region retains essentially full biological activity of the 44-amino-acid full-length GHRH.
Mechanism
Sermorelin binds the GHRH receptor (GHRHR) on anterior pituitary somatotrophs. Receptor activation triggers:
- cAMP/PKA pathway activation
- GH gene transcription
- GH synthesis
- GH release from secretory granules
This is a true “secretagogue” mechanism — sermorelin causes the pituitary to make and release its own GH, rather than supplying exogenous GH.
Pharmacokinetics
- Route: Subcutaneous injection
- Half-life: ~11-12 minutes (very short)
- Peak GH response: 30-60 minutes post-injection
- Duration of GH elevation: 2-4 hours
The short half-life is a design feature — sermorelin produces a discrete GH pulse rather than sustained elevation, mimicking natural pulsatile release.
Clinical and research applications
GH deficiency diagnostic testing
Original FDA approval (1990, brand name Geref) was for diagnosing GH deficiency. Patients with intact pituitary respond to sermorelin with normal GH release; those with pituitary-level deficiency show blunted response.
GH therapy alternative
For mild GH deficiency or healthy aging where some endogenous GH production is preserved, sermorelin offers an alternative to direct exogenous GH (somatropin):
- Preserves pulsatile GH release pattern
- Maintains negative feedback regulation (less risk of supraphysiologic exposure)
- No suppression of endogenous GHRH
Anti-aging / age-related GH decline
Used in age management clinics to address declining GH production. Evidence for clinical benefit in this population is limited but mechanism is plausible.
Dosing protocols
Standard reported protocols:
- Diagnostic dose: 1 µg/kg IV bolus (single dose for GH testing)
- Therapeutic dose: 200-500 µg subcutaneous, 1-3x daily
- Pre-bed dosing: Aligns with natural GH peak during slow-wave sleep
- Cycle: 8-12 weeks on, 4 weeks off
Sermorelin vs CJC-1295
| Sermorelin | CJC-1295 No-DAC | CJC-1295 DAC | |
|---|---|---|---|
| Amino acids | 29 (GHRH 1-29) | 30 (modified GHRH 1-29) | 30 + DAC linker |
| Half-life | ~12 min | ~30 min | ~6-8 days |
| Dosing frequency | 2-3x daily | 2-3x daily | Weekly |
| FDA status | Approved 1990 (discontinued marketing) | Not approved | Not approved |
Why sermorelin’s commercial marketing was discontinued
The original commercial product (Geref/Geref Diagnostic) was withdrawn in 2008 by EMD Serono. Reasons were primarily commercial — the diagnostic testing market was small and competitors offered alternative diagnostic tools. The molecule remains legally available through compounding pharmacies and research suppliers.
Side effects
Notably mild side effect profile:
- Injection-site redness or itching (most common)
- Transient flushing
- Headache (rare)
- Possible insulin sensitivity changes with chronic high-dose use
Is sermorelin the same as GHRH?<br />
Sermorelin is the (1-29) fragment of GHRH. The full-length endogenous GHRH is 44 amino acids; the first 29 contain the biologically active region.
Sermorelin vs HGH — which is safer?<br />
Sermorelin works through the natural pituitary feedback loop, preserving normal regulatory mechanisms. Exogenous HGH bypasses this regulation. Sermorelin generally has better safety profile but smaller effect size.
Can sermorelin be combined with ipamorelin?<br />
Yes — this is the original GHRH+GHRP combination (predates CJC-1295/Ipamorelin protocols). Sermorelin’s short half-life means it must be co-dosed with each ipamorelin injection.
How long do sermorelin effects last?<br />
Each injection produces a 2-4 hour GH pulse. IGF-1 elevation builds over days of consistent dosing and persists for similar duration after stopping.